SynthesisHormones (Athens, Greece)2022
The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.
Synthesis in Hormones (Athens, Greece), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Article
- mLeveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes.The pharmacogenomics journal · 2025Article
- Allopurinol use predicts lower low-density lipoprotein cholesterol in patients with pre-dialysis chronic kidney disease-a prospective cohort study.Clinical kidney journal · 2025Article
- New approach to optimize therapy in type 2 diabetes mellitus: the importance of subclassification.Frontiers in endocrinology · 2025Review
- Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases.Reviews in cardiovascular medicine · 2023Review
- Activation of the Nrf-2/HO-1 signalling axis can alleviate metabolic syndrome in cardiovascular disease.Annals of medicine · 2023Review
- Genetics of hyperaldosteronism and a wealth of new information on topics ranging from MEN1 to Cushing's disease and metabolic syndrome.Hormones (Athens, Greece) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) remains the main cause of death in patients with type 2 diabetes (T2D). Although hyperuricemia has been associated with multiple CV complications, it is not officially recognized as a target parameter for CVD risk reduction.
aimTo systematically review the literature in order to determine whether treating hyperuricemia with allopurinol in patients with T2D reduces CVD risk.
methodsA thorough literature search in the PubMed, CENTRAL, and EMBASE databases from inception to August 2022 was performed. After application of selection criteria, 6 appropriate studies were identified.
resultsDetailed analysis of the data derived indicated that there is an association between allopurinol treatment and CV benefits, resulting in a reduced risk of CVD events and mortality rates. This association can be attributed mainly to the reduction of inflammation and oxidative burden, as well as to the improvement of glycemic and lipid profiles.
conclusionsThis systematic review provides evidence that allopurinol may reduce CVD risk in patients with T2D. Randomized, placebo-controlled trials should be performed in order to confirm these findings and identify specific subgroups of patients who will benefit most.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.